CYP2B6 and central nervous system cancer: The animal model reported in this work could be used to explore changes in CPA pharmacokinetics and anti-tumor activity when pre-treatment to induce CYP2B6 is used, since the model has high basal expression of CYP2B6 in the tumor tissue as occurs in pediatric gliomas.